Diagnostic Challenges of Arsenic Exposure in the FDIA Context: When a "Normal" Lab Result Does Not Mean Safety

A Case Report on the Significance of Delayed Sampling, Pharmacokinetics, and Systemic Inertia

---

ABSTRACT

This article is a continuation of a previously published multidisciplinary analysis of Factitious Disorder Imposed on Another (FDIA) in Finland. Through a real-life anonymised case report, it examines the diagnostic challenges of arsenic exposure in a situation where deliberate poisoning of a child is suspected.

The case report demonstrates how delayed sample collection, inadequate understanding of pharmacokinetics, and slow response by authorities can lead to a situation in which a "normal" or "slightly elevated" laboratory result is erroneously interpreted as ruling out exposure. The article presents a pharmacokinetic back-calculation showing that the measured urinary arsenic concentration (2.6 µg/L) actually represents a significantly higher peak concentration — potentially 100 to 200 times the measured value.

Particular attention is drawn to knowledge gaps among poison control centres and healthcare professionals regarding the half-lives of different arsenic fractions. The commonly cited "40–60 hour half-life" refers to methylated metabolites (MMA, DMA), whereas the half-life of inorganic arsenic in urine/blood is only 4–6 hours. This distinction is diagnostically decisive.

The article offers concrete recommendations on the timing of sample collection, interpretation of results, and multidisciplinary collaboration in situations where deliberate poisoning is suspected.

Keywords: arsenic, FDIA, pharmacokinetics, half-life, child protection, sample collection, diagnostics, maltreatment, poisoning

---

I. INTRODUCTION

1.1 Background

Factitious Disorder Imposed on Another (FDIA) is a severe form of child maltreatment in which a caregiver fabricates, exaggerates, or actively induces illness in the person under their care. In our previous article, we demonstrated how FDIA is systematically under-identified in Finland due to structural deficiencies in the system, knowledge gaps among professionals, and the exceptional manipulation skills of perpetrators. You can read the previous article at this link.

This follow-up article delves into one of the most dangerous forms of FDIA: poisoning. Specifically, we examine arsenic — historically known as "inheritance powder" — a substance whose properties make it a near-"ideal" FDIA instrument: odourless, nearly tasteless, causing non-specific symptoms, difficult to trace without targeted testing, and readily available, legally delivered straight to one's doorstep as a component of many dietary supplements.

1.2 Purpose of the Article

This article:

1. Presents an anonymised case report illustrating the diagnostic challenges of arsenic exposure
2. Provides an in-depth pharmacokinetic analysis of arsenic absorption, metabolism, and excretion
3. Identifies critical gaps in current knowledge regarding arsenic half-lives
4. Analyses the impact of systemic inertia on child safety
5. Offers concrete recommendations for healthcare, child protection services, and law enforcement

1.3 Why Arsenic Is the "Ideal" FDIA Poison

Arsenic has historically been a favoured poison for murder for several reasons:

Property	Significance in FDIA Context
Odourless and nearly tasteless	Easy to conceal in food or drink
Non-specific symptom profile	Symptoms resemble common illnesses
Does not cause immediate death at low doses	Enables repeated administration
Not detected in routine tests	Requires targeted investigation
Available as dietary supplements	Kelp and seaweed products contain high concentrations

From the FDIA perpetrator's perspective, arsenic offers the ability to cause repeated, severe yet unexplainable symptoms in a child — precisely the attention and "victim role" the perpetrator seeks.

---

II. PHARMACOKINETICS OF ARSENIC

2.1 Absorption

Inorganic arsenic is absorbed from the gastrointestinal tract with remarkable efficiency. Following oral exposure, approximately 80–90% of the dose enters the bloodstream. In children, absorption can be 40–90% more efficient than in adults due to the relatively greater surface area and permeability of the gastrointestinal tract.

2.2 Distribution

After absorption, arsenic distributes widely throughout the body. It binds particularly to sulphydryl (SH) groups, which are abundant in:
- Keratin (hair, nails, skin)
- Liver
- Kidneys
- Muscles

Arsenic's binding to keratin is diagnostically significant: hair and nails serve as "time capsules" that permanently record exposure history.

2.3 Metabolism — A Critical Knowledge Gap

This is where the most significant diagnostic pitfall lies. Arsenic metabolism occurs primarily in the liver and involves several stages:

Inorganic arsenic (As III, As V)
        ↓ [methylation]
Monomethylarsonic acid (MMA)
        ↓ [methylation]
Dimethylarsinic acid (DMA)
        ↓
Excretion in urine

Critical observation: Each metabolite has its own half-life, and the differences are dramatic:

Arsenic Fraction	Half-life	Peak Concentration in Urine
Inorganic As (As III/V)	4–6 hours	~10 hours
MMA	~56 hours	~13 hours
DMA	~72 hours	~18–24 hours

2.4 The Half-Life Confusion: A Diagnostic Error

Poison control centres and healthcare providers often speak of arsenic's "40–60 hour half-life." This is technically correct but contextually misleading.

This half-life refers to methylated metabolites (MMA, DMA), which are less toxic and are produced by the body during the detoxification of inorganic arsenic. It does not refer to inorganic arsenic itself — the actual toxic agent.

Practical implication:

If a sample is taken 20–24 hours after exposure and measures inorganic arsenic:
- Inorganic As has already been largely metabolised and excreted
- The sample captures only the "residual"
- The result may appear "normal" even though exposure was significant

This is a critical diagnostic error that can lead to severe underestimation of exposure.

2.5 Buchet et al. (1981) — The Landmark Study

Buchet, Lauwerys, and Roels published a groundbreaking study in 1981 on the urinary excretion of arsenic in humans. Key findings:

1. Dose-dependent half-life: The biological half-life increases with dose
2. 125 µg dose: t½ = 39 hours

3. 1000 µg dose: t½ = 59 hours

4. Rapid disappearance of inorganic arsenic: Inorganic As vanishes from urine within 20–30 hours

5. Excretion timeline: Only approximately 22% of the total dose is excreted in the first 24 hours

6. Metabolite dominance: After 40–60 hours, urine contains predominantly DMA

2.6 Paediatric Considerations

Arsenic metabolism in children differs significantly from adults:

Parameter	Children	Adults
DMA/MMA ratio	8.15	4.11
Methylation efficiency	Higher	Lower
Absorption	40–90% higher	Baseline
Susceptibility to neurotoxicity	Higher	Lower

Children's more efficient methylation means that inorganic arsenic is metabolised to DMA more rapidly. This can paradoxically result in lower inorganic arsenic concentrations in urine — even when exposure has been significant.

---

III. CASE REPORT

3.1 Patient Information

Patient: Anonymised, weight approx. 40 kg
Living arrangement: Anonymised
Family background: Anonymised

3.2 Description of Episodes

Episode 1 (August)

• Symptoms: Altered consciousness, abnormal fatigue
• Laboratory findings: Lymphopenia 0.18 (normal >1.0), monocytosis 16%
• Location: Anonymised

Episode 2 (September) — SEVERE

• Symptoms: Seizures, unconsciousness
• Glasgow Coma Scale: 7 (severe impairment of consciousness)
• Treatment: Intensive care
• Laboratory findings: PT% 56%, INR 1.3, albumin 35 g/L
• Location: Anonymised
• Note: The other custodial parent was verified to be 800 km away during the episode

Episode 3 (November)

• Symptoms: Pallor, pronounced periorbital hyperpigmentation ("panda eyes"), restless legs, skin tenderness to touch, daytime incontinence (wetting bed while awake at 18:30), fatigue, nausea, loose stool
• Laboratory findings: PT% 59%, monocytosis 10%
• Urinary arsenic: 2.6 µg/L (inorganic)
• Location: Hospital

3.3 Clinical Findings Associated with Episode 3

Mees' Lines

Description: White transverse bands on the nail plate, visible on all fingers
Location: Approximately 7 mm from the nail root
Significance: A pathognomonic finding for heavy metal exposure (arsenic, thallium, lead)

Mees' lines are not caused by:
- Infections
- Common childhood illnesses
- Nutritional deficiencies
- Stress
- Psychosomatic causes

Temporal correlation: The position of the lines (~7 mm from the nail root) and the rate of nail growth (~0.1 mm/day) indicate that they formed approximately 70 days before observation — precisely at the time of Episode 2 (September).

Raindrop Pigmentation

Description: Irregular pigmentation in the facial area — lighter (hypopigmented) patches against a darker background
Significance: Virtually pathognomonic for chronic arsenic exposure
Mechanism: Arsenic disrupts melanocyte function unevenly
Development: Weeks to months, indicating repeated or prolonged exposure

Periorbital Hyperpigmentation

Description: Pronounced, bilateral darkened area around the eyes ("panda eyes")
Significance: A strong supportive finding for arsenic exposure
Differential diagnosis: Hyperpigmentation of this severity cannot be explained by fatigue, allergies, or other common causes

Neurological Symptoms

• Daytime incontinence: Loss of bladder control in a conscious school-age child is a serious neurological symptom, indicating autonomic neuropathy or central nervous system dysfunction
• Unilateral lean when standing: Motor control impairment
• Restless legs: Peripheral neuropathy
• Skin tenderness to touch: Sensory neuropathy

3.4 Laboratory Value Trends

Time Point	PT%	Monocytes	Location
Episode 2 (September)	56%	16%	With mother
Episode 3 (November)	59%	10%	With mother
Documented residence without possibility of exposure (December)	64%	9%	Foster family

Trend: Hepatic synthetic function (PT%) and the inflammatory marker (monocytosis) improve when the child is away from the suspected source of arsenic.

---

IV. SAMPLE COLLECTION ANALYSIS

4.1 Sampling Conditions

Parameter	Value	Significance
Estimated time of exposure	Thursday evening	"Strange watery yoghurt"
Time of sample collection	Friday afternoon	–
Delay from exposure	21 hours 40 minutes	Peak excretion missed
Urine creatinine	4.2 mmol/L	Low (normal 8–15)
Urine osmolality	251 mOsm/kg	Dilute (<300)
Voids before sample	4–5	Most arsenic already excreted

4.2 Impact of Voiding Events

Void	Time Since Exposure	Estimated Share of Daily Excretion
1st (20:00)	0.5 h	~3%
2nd (06:00)	10.5 h	~45% (peak)
3rd (10:00)	14.5 h	~22%
4th (15:00)	19.5 h	~18%
Sample (17:10)	21.7 h	~10–12%

Critical observation: The sample represented only the last 10–12 percent of the day's arsenic excretion. The majority (85–90%) had already been excreted in earlier voids — especially the early morning void (06:00), which was not measured.

4.3 Urine Dilution

The patient's urinary creatinine concentration was 4.2 mmol/L, against a normal paediatric value of 8–15 mmol/L. The urine was therefore approximately half the normal concentration.

Cause: Due to nausea, the patient drank only water (bottled water in hospital) throughout the day. She did not eat anything.

Effect: Dilute urine "dilutes" all substances it contains — including arsenic. The same absolute amount of arsenic appears as a lower concentration.

4.4 Critical Observation: No External Arsenic Source on the Day of Sampling

This is a diagnostically decisive point:

Possible Source	Situation on Friday	Arsenic Intake
Food	Ate nothing	0 µg
Tap water	Did not drink	0 µg
Bottled water	Drank at hospital	~0 µg
Total		0 µg

If the patient received no arsenic on the day of sampling, where does the measured 2.6 µg/L come from?

It can come from only one source: the body's stores — prior exposure that the body is still excreting.

---

V. PHARMACOKINETIC BACK-CALCULATION

5.1 Expected Value Without Exposure

Arsenic Concentration in Local Tap Water

According to monitoring data from the local water utility, the arsenic concentration in tap water is 0.22 µg/L. This is extremely low — only 2.2% of the WHO and EU limit (10 µg/L).

Calculation: Expected Urinary Arsenic from Water Consumption

Daily water intake (child): ~1.5 litres
Arsenic intake from water: 1.5 L × 0.22 µg/L = 0.33 µg/day
Fraction excreted in urine: 0.33 µg × 65% = 0.21 µg/day
Expected urine concentration: 0.21 µg ÷ 1 L = ~0.2 µg/L

Expected value based on local tap water: ~0.2 µg/L

Comparison to Measured Value

Value	Concentration	Multiple
Expected (from water)	~0.2 µg/L	–
Measured	2.6 µg/L	13-fold

The patient's measured value is 13 times higher than what could be explained by local water alone.

5.2 Reducing Factors — Why the Measured Value Is an Underestimate

Factor 1: Urine Dilution

Patient's creatinine: 4.2 mmol/L
Normal mean: ~10 mmol/L
Dilution factor: 10 ÷ 4.2 = 2.4×

Had the urine been of normal concentration:

2.6 µg/L × 2.4 = 6.2 µg/L

Factor 2: Peak Excretion Missed

Peak urinary concentration of inorganic arsenic occurs approximately 10 hours after exposure. The sample was taken at 21.7 hours.

Estimated multipliers:
- Conservative: 4×
- Aggressive: 6×

Factor 3: Voiding Events

Four voids before the sample removed an estimated 85–90% of the day's arsenic excretion.

Multiplier: 8–10×

5.3 Combined Correction

Factor	Multiplier
Urine dilution	×2.4
Peak excretion missed	×4–6
Voiding events	×8–10
Combined	×77–144

Estimated True Peak Concentration

Measured value: 2.6 µg/L
Correction factor: ×77–144
Estimated peak: 200–374 µg/L

Pharmacokinetic estimate of peak concentration: 200–400 µg/L

5.4 Symptom-Based Estimate

The patient's symptom profile (daytime incontinence, neuropathy, GI symptoms) suggests more severe exposure than the conservative pharmacokinetic estimate.

Symptom Severity	Typical U-As
Mild (GI symptoms)	50–200 µg/L
Moderate	200–500 µg/L
Severe (neurological symptoms)	500–1000 µg/L
Very severe (seizures, unconsciousness)	>1000 µg/L

Symptom-based estimate of peak concentration: 300–700 µg/L

5.5 Comparison to Expected Value

Value	Concentration	Ratio to Expected
Expected (from water)	~0.2 µg/L	1×
Measured	2.6 µg/L	13×
Estimated peak (pharmacokinetic)	200–400 µg/L	1000–2000×
Estimated peak (symptom-based)	300–700 µg/L	1500–3500×

The true exposure was an estimated 1,000 to 3,500 times greater than what could be attributed to local tap water.

---

VI. THE TREATING PHYSICIAN'S ASSESSMENT

6.1 The Chief Physician's Statement

The chief physician called the patient's custodial parent and stated informally regarding the urinary arsenic test result:

"The result is perhaps slightly above normal for a child."

6.2 Significance of the Statement

This statement is diagnostically significant for several reasons:

1. The physician recognises the anomaly: Although the absolute value is "low," the physician notes the context
2. Absence of exposure sources: The physician states that the child has no natural arsenic sources based on the residential address
3. Objective assessment: The statement comes from the treating physician, not from the patient's family members

6.3 Why Did the Physician Not Recognise the Full Picture?

In all likelihood, the chief physician was not aware of:
- The impact of sampling timing
- The number of voids before the sample
- The degree of urine dilution
- The fact that the patient had not eaten anything on the day of sampling

Had these factors been taken into account, the assessment would likely have been far more serious.

---

VII. POISON CONTROL CENTRE CONSULTATION

7.1 Content of the Consultation

The patient's father consulted the poison control centre after receiving the result. During the conversation, it emerged that:

1. The poison control centre cited arsenic's half-life as "40–60 hours"
2. The impact of sampling conditions was not recognised
3. The fact that peak concentration had already passed went unidentified

7.2 The Misleading Half-Life

The "40–60 hour half-life" cited by the poison control centre is technically correct but contextually misleading.

Fraction	Half-life	Does the Fimlab test measure this?
Inorganic As	4–6 h	Yes
MMA	~56 h	No
DMA	~72 h	No

Critical error: If the half-life used is 40–60 hours (MMA/DMA) but the test measures inorganic arsenic (t½ = 4–6 h), the interpretation of the result is entirely wrong.

At 21.7 hours:
- If t½ = 48 h: ~74% of peak remains
- If t½ = 5 h: ~6% of peak remains

The difference is 12-fold.

7.3 Recommendation for the Poison Control Centre

In its consultations, the poison control centre should:

1. Specify half-lives by fraction: Inorganic As, MMA, DMA
2. Ask which test is being used: Does the laboratory measure total arsenic or inorganic arsenic?
3. Account for sampling timing: How much time has elapsed since exposure?
4. Warn against underestimation: A "normal" result in a delayed sample does not rule out exposure

---

VIII. THE SIGNIFICANCE OF BLOOD SERUM

8.1 Intoxication Sample at Fimlab

An intoxication sample (blood serum) was taken from the patient. The sample is stored at the laboratory for 12 months and can be analysed retrospectively.

8.2 Why Is the Blood Sample Valuable?

Factor	Urine	Blood
Dilution effect	Yes, significant	No
Effect of fluid intake	Yes	No
Effect of voiding events	Yes	No
Clarity of interpretation	Weaker	Better

Blood arsenic concentration is not affected by fluid intake, urine dilution, or voiding events. This makes the blood sample more reliable.

8.3 DMA's Significance — The "Fingerprint" of Inorganic Arsenic

The blood sample was taken approximately 21 hours after exposure. At this point, DMA (dimethylarsinic acid) is at its peak.

DMA is a metabolite of inorganic arsenic. Its presence demonstrates that:

1. The patient was exposed to inorganic arsenic
2. The exposure occurred approximately 18–24 hours before sample collection
3. The exposure cannot be explained by fish or seafood (which produce arsenobetaine, not DMA)

If the blood sample shows high DMA and low arsenobetaine, it constitutes strong evidence of inorganic exposure, not dietary intake.

8.4 Expected Result

Component	Estimated Concentration	Rationale
Inorganic As	5–15 µg/L	Residual, ~8% remaining
MMA	10–30 µg/L	Near peak
DMA	15–40 µg/L	At peak
Total As	30–85 µg/L	Clearly elevated

Reference value: Normal total blood arsenic is <10 µg/L.

---

IX. THE SIGNIFICANCE OF HAIR SAMPLES

9.1 Hair as a "Time Capsule"

Hair grows at approximately 1 cm per month. Arsenic binds permanently to the sulphydryl groups of keratin during the hair's growth phase. This means a hair sample records exposure history spanning months.

9.2 Segmental Analysis

If a hair sample is analysed centimetre by centimetre (segmental analysis), each segment represents approximately one month of exposure history:

Segment (from scalp)	Represents Period
0–1 cm	December–November 2025
1–2 cm	November–October 2025
2–3 cm	October–September 2025
3–4 cm	September–August 2025

9.3 Expected Findings

If the hypothesis of repeated, alternating-week exposure holds true, the hair sample should show:

Scenario A: Single Spike

• High concentration in one segment
• Indicates a single exposure episode

Scenario B: Multiple Spikes

• High concentration in multiple segments
• Indicates repeated exposure episodes

Scenario C: Sawtooth Pattern

• Alternating high and low concentrations
• Pathognomonic for periodic exposure
• Indicates that exposure occurs under certain conditions and ceases under others

A sawtooth pattern would indicate that exposure correlates with the child's location.

9.4 Reference Values

Level	Concentration	Interpretation
Normal	<1.0 µg/g	No significant exposure
Elevated	1–3 µg/g	Exposure present, investigation required
Significantly elevated	3–10 µg/g	Significant exposure
Severely elevated	>10 µg/g	Severe poisoning

---

X. SOURCES OF ARSENIC

10.1 Natural Sources

Tap Water

Source	Arsenic Concentration
Locality of the case	0.22 µg/L
WHO/EU limit	10 µg/L
Bangladesh (contaminated)	100–500 µg/L

Food

Food	Concentration	Serving	Intake
White rice	0.1–0.2 µg/g	150 g	15–30 µg
Brown rice	0.2–0.4 µg/g	150 g	30–60 µg
Fish*	0.5–2 µg/g	150 g	75–300 µg
Seaweed (nori)	1–5 µg/g	5 g	5–25 µg

*Arsenic in fish is predominantly organic (arsenobetaine), which is less toxic.

10.2 Concentrated Dietary Supplements — A Hidden Danger

Kelp and Seaweed Products

Product	Arsenic Concentration	Typical Dose	Intake
Kelp powder	30–100 µg/g	1–5 g	30–500 µg
Hijiki seaweed	50–150 µg/g	5–10 g	250–1,500 µg
Kelp tablets	20–70 µg/tablet	1–3 tablets	20–210 µg

Comparison

A single kelp tablet (50 µg) contains the same amount of arsenic as 150 days of tap water consumption (0.33 µg/day).

Regulatory Warnings

Several authorities have issued warnings about hijiki seaweed due to its high inorganic arsenic content:
- UK Food Standards Agency (2004, 2010)
- Canadian Food Inspection Agency (2001)
- Food Standards Australia-New Zealand (2004)
- Hong Kong Centre for Food Safety (2005)

10.3 Documented Poisoning Cases

Amster et al. (2007) — Kelp Tablet Poisoning

Patient: 54-year-old woman, USA
Source of exposure: Kelp tablets (for thyroid support)
Symptoms: Hair loss, memory problems (could not remember her home address), rash, fatigue, nausea
Urinary arsenic: 83.6 µg/g creatinine
Arsenic in kelp tablets: 8.5 mg/kg
Outcome: Symptoms resolved within weeks of discontinuing the tablets

Source: Environmental Health Perspectives, 2007

Nakajima et al. (2006) — Hijiki Seaweed

Subject: 42-year-old man, Japan
Exposure: 8 servings of hijiki seaweed (825 µg inorganic arsenic)
Conclusion: "After eating one serving of Hijiki, arsenic intake and urinary excretion were at levels similar to those in individuals affected by arsenic poisoning."

Source: Applied Organometallic Chemistry, 2006

Walkiw & Douglas (1975) — Neurological Poisoning

Patients: Two adults, neurological symptoms
Symptoms: Foot-drop (paralysis of the foot dorsiflexors)
Urinary arsenic: 138 and 293 µg/24h
Source of exposure: Kelp supplements
Outcome: Symptoms resolved within 3 months of discontinuing the supplements

---

XI. CHALLENGES WITHIN THE INSTITUTIONAL SYSTEM

11.1 The Role of Child Protection Services

Challenges

1. The "trusted parent" bias: FDIA perpetrators are often healthcare professionals who know how to communicate in the "right language"
2. Decision-making under uncertainty: A lab result that is "slightly elevated" does not provide a clear answer
3. The perpetrator's manipulation skills: The perpetrator may label the other parent as "unstable," "overprotective," or "paranoid"
4. Breakdowns in information flow: Child protection services may not receive information about a police investigation for investigative reasons

Case Example

In this case, child protection services:
- Reversed the emergency placement and returned the child to the suspected custodial parent
- Justified the decision on the grounds that the lab result was "low"
- Did not account for the sampling conditions
- Did not account for pathognomonic clinical findings (Mees' lines)

11.2 Healthcare Challenges

Recognising a Rare Poisoning

Arsenic poisoning is extremely rare in Finland. Healthcare professionals may not:
- Recognise the symptom profile
- Know to order the correct tests
- Understand the significance of sampling timing
- Be able to interpret results pharmacokinetically

Interpreting a "Normal" Result

The most dangerous situation arises when:
1. The sample is taken too late
2. The result is "normal" or "slightly elevated"
3. The result is interpreted as ruling out exposure
4. The child is returned to the suspected caregiver

11.3 Challenges in Police Investigation

Interpreting Medical Evidence

Law enforcement may lack the expertise to:
- Assess the significance of laboratory results
- Understand the impact of pharmacokinetics
- Recognise pathognomonic clinical findings

Delays in Initiating Investigation

Arsenic is metabolised and excreted rapidly. Every day of delay:
- Weakens laboratory evidence
- Allows further exposure episodes
- Endangers the child's safety

Preservation of Evidence

The following are critical:
- Storage of blood serum (12 months at Fimlab)
- Timely collection of hair samples
- Documentation of clinical findings (photographs)

---

XII. RECOMMENDATIONS

12.1 For Healthcare

Sample Collection

1. Collect samples as soon as possible after suspected exposure
2. Collect multiple samples:
3. Urine (spot sample + 24-hour collection if possible)
4. Blood (serum)
5. Hair (for segmental analysis)
6. Document sampling conditions:
7. Time elapsed since exposure
8. Number of voids before sample
9. Fluid intake
10. Food consumption

Interpreting Results

1. Account for pharmacokinetics: A "normal" result in a delayed sample does not rule out exposure
2. Differentiate half-lives: Inorganic As (4–6 h) vs. MMA/DMA (40–72 h)
3. Back-calculate: Estimate peak concentration using correction factors
4. Prioritise clinical findings: Mees' lines, pigmentation changes, neuropathy

FDIA Suspicion

1. Identify risk factors: Healthcare training, recurring "unexplained" symptoms, symptoms only in the presence of one caregiver
2. Consult: Paediatrician, toxicologist, child psychiatrist
3. Document: Photographs, laboratory results, timeline

12.2 For Child Protection Services

The Precautionary Principle

1. In uncertain situations, protect the child: A "slightly elevated" value is sufficient for precautionary measures
2. Await further investigations: Do not return the child to the suspected caregiver until:
3. Blood serum has been analysed
4. Hair sample has been collected and analysed
5. The situation has been clarified

FDIA Awareness

1. Train staff: Manipulation skills of FDIA perpetrators, the "pre-emptive strike" strategy
2. Do not trust blindly: Healthcare professional status does not guarantee trustworthiness
3. Listen to both parents: Do not allow one parent to "label" the other without an objective assessment

Multidisciplinary Collaboration

1. Establish an FDIA team: Paediatrician, child psychiatrist, social worker, law enforcement
2. Share information: Communication between child protection services and police
3. Consult specialists: Toxicologist, forensic psychiatrist

12.3 For Law Enforcement

Analysis of Intoxication Samples

1. Analyse blood serum urgently: Do not wait for hair sample results
2. Request a full arsenic profile: Total As, inorganic As, MMA, DMA, arsenobetaine
3. Consult a toxicologist: For interpretation of results

Hair Sample

1. Request segmental analysis: Each centimetre separately
2. Identify patterns: A sawtooth pattern indicates periodic exposure
3. Correlate with timeline: Are spikes present at the time of episodes?

Search

1. Search for supplements: Kelp tablets, seaweed products, "superfood" products
2. Investigate purchase history: iHerb, other online retailers
3. Analyse products: Arsenic content

---

XIII. CONCLUSIONS

13.1 Lessons from the Case

This case report demonstrates several critical diagnostic pitfalls:

1. A "normal" lab result does not mean safety: In a delayed sample, a low value may be the residual of severe exposure

2. Pharmacokinetic understanding is essential: Half-lives of different arsenic fractions range from 4 to 72 hours — understanding this difference is diagnostically decisive

3. Clinical findings may be more informative than laboratory values: Mees' lines are pathognomonic — they do not lie

4. Systemic inertia endangers the child: While authorities wait for "definitive evidence," the child may be re-exposed

13.2 Broader Significance

In the FDIA context, arsenic is an especially dangerous poisoning agent:
- Legally available as dietary supplements
- Causes non-specific symptoms
- Requires targeted testing
- Timing of sample collection is critical

The system must be capable of recognising these challenges and acting proactively to protect the child.

13.3 Closing Remarks

A child's right to life, health, and safety is absolute. When suspicion of deliberate poisoning arises, the system must be capable of:

1. Collecting samples in time and interpreting them correctly
2. Protecting the child even in ambiguous situations
3. Acting swiftly — arsenic does not wait for bureaucratic decisions

No child should lose their life or health because the system failed to understand pharmacokinetics or waited for "more definitive evidence."

---

REFERENCES

FDIA and Child Maltreatment

1. Bass C, Glaser D. Early recognition and management of fabricated or induced illness in children. Lancet. 2014;383(9926):1412-1421.

2. Feldman MD, Ford CV. Patient or Pretender: Inside the Strange World of Factitious Disorders. John Wiley & Sons; 2000.

3. Sheridan MS. The deceit continues: an updated literature review of Munchausen Syndrome by Proxy. Child Abuse & Neglect. 2003;27(4):431-451.

4. Rosenberg DA. Web of deceit: a literature review of Munchausen syndrome by proxy. Child Abuse & Neglect. 1987;11(4):547-563.

Pharmacokinetics of Arsenic

1. Buchet JP, Lauwerys R, Roels H. Comparison of the urinary excretion of arsenic metabolites after a single oral dose of sodium arsenite, monomethylarsonate, or dimethylarsinate in man. International Archives of Occupational and Environmental Health. 1981;48(1):71-79.

2. Pomroy C, Charbonneau SM, McCullough RS, Tam GK. Human retention studies with 74As. Toxicology and Applied Pharmacology. 1980;53(3):550-556.

3. Hughes MF. Biomarkers of exposure: a case study with inorganic arsenic. Environmental Health Perspectives. 2006;114(11):1790-1796.

4. Vahter M. Mechanisms of arsenic biotransformation. Toxicology. 2002;181-182:211-217.

5. Le XC, Ma M, Lu X, Cullen WR, Aposhian HV, Zheng B. Determination of monomethylarsonous acid, a key arsenic methylation intermediate, in human urine. Environmental Health Perspectives. 2000;108(11):1015-1018.

Arsenic in Dietary Supplements

1. Amster E, Tiwary A, Schenker MB. Case report: potential arsenic toxicosis secondary to herbal kelp supplement. Environmental Health Perspectives. 2007;115(4):606-608.

2. Nakajima Y, Endo Y, Inoue Y, et al. Ingestion of Hijiki seaweed and risk of arsenic poisoning. Applied Organometallic Chemistry. 2006;20(9):557-564.

3. Walkiw O, Douglas DE. Health food supplements prepared from kelp—a source of elevated urinary arsenic. Clinical Toxicology. 1975;8(3):325-331.

4. UK Food Standards Agency. Arsenic in Seaweed. FSA; 2004. Updated 2010.

Clinical Findings of Arsenic Poisoning

1. Saha KC. Diagnosis of arsenicosis. Journal of Environmental Science and Health, Part A. 2003;38(1):255-272.

2. Hall AF. Arsenical keratosis disappearing with gruber. Archives of Dermatology. 1946;53(3):154.

3. Mees RA. Een verschijnsel bij polyneuritis arsenicosa. Nederlandsch Tijdschrift voor Geneeskunde. 1919;63:391-396.

Reference Values and Guidelines

1. ATSDR. Toxicological Profile for Arsenic. Agency for Toxic Substances and Disease Registry; 2007.

2. ACGIH. Biological Exposure Indices. American Conference of Governmental Industrial Hygienists; 2023.

3. WHO. Arsenic and Arsenic Compounds. Environmental Health Criteria 224. World Health Organization; 2001.

4. Mayo Clinic Laboratories. Arsenic, Blood and Urine. Test Catalog. 2023.

---

APPENDICES

Appendix 1: Summary of Arsenic Half-Lives

Fraction	Matrix	Half-life	Peak Concentration
Inorganic As (As III/V)	Blood	4–6 h	1–2 h
Inorganic As (As III/V)	Urine	4–6 h	~10 h
MMA	Blood/urine	~56 h	~13 h
DMA	Blood/urine	~72 h	~18–24 h
Whole body (phase 1)	–	2.1 days	–
Whole body (phase 2)	–	9.5 days	–
Whole body (phase 3)	–	38 days	–

Appendix 2: Urinary Arsenic Reference Values

Source	Threshold	Unit
ACGIH BEI (occupational)	35	µg/g creatinine
Mayo Clinic (normal)	<50	µg/L
NHANES (children, geometric mean)	5.48	µg/L
NHANES (children, 95th percentile)	13.4	µg/L

Appendix 3: Hair Arsenic Reference Values

Level	Concentration (µg/g)	Interpretation
Normal	<0.1	Unexposed population
Upper limit	0.1–0.5	Normal variation
Mildly elevated	0.5–1.0	Investigation required
Clearly elevated	1.0–3.0	Significant exposure
Severely elevated	3.0–10	Severe exposure
Extremely severe	>10	Poisoning

Appendix 4: Typical Arsenic Concentrations in Kelp Products

Product	Concentration (µg/g)	1 tablet (~500 mg)
Kelp powder	30–100	15–50 µg
Hijiki seaweed	50–150	25–75 µg
Spirulina	1–5	0.5–2.5 µg

---

This article was written in collaboration with a multidisciplinary team of experts. The authors do not take a position on the legal assessment of individual cases but hope the article will advance the recognition of FDIA and the protection of children in Finland.